Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Scribe Therapeutics Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 examiners across 5 art units, indicating a broad and distributed prosecution profile. The examiner assignments exceed the art-unit assignments, so some art-unit context is shared even though the matters have separate examination contacts.
SPENCE, JENNIFER SUZANNE is the busiest examiner, with 1 pending matter. No examiner has a larger pending allocation in the supplied data, making application-level coordination important.
Counsel should maintain a central claim and disclosure strategy while adapting responses to the applicable art unit and examiner. The 5-art-unit spread also makes consistent explanations of biotechnology concepts important, particularly where related applications present similar technical issues in different examination settings.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 2 (29%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.4% | +46.6% |
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.1% |
| ZARA, JANE J | 1 | 71.1% | +16.1% |
| SU-TOBON, QIWEN NMN | 1 | 75.0% | +66.7% |
| MCLEOD, AFRICA MHAIRIE | 1 | 58.6% | +58.1% |
| RYAN, DOUGLAS CHARLES | 1 | 37.7% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039858 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | ZARA, JANE J | 51d overdue |
| 17641426 | COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 | RYAN, DOUGLAS CHARLES | 31d overdue |
| 18266076 | AAV VECTORS FOR GENE EDITING | CHONG, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039858 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | ZARA, JANE J | 51d overdue |
| 17641426 | COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 | RYAN, DOUGLAS CHARLES | 31d overdue |
| 18693062 | ENGINEERED CASX REPRESSOR SYSTEMS | SPENCE, JENNIFER SUZANNE | — |
| 18266076 | AAV VECTORS FOR GENE EDITING | CHONG, KIMBERLY | — |
| 18255172 | COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A | SU-TOBON, QIWEN NMN | — |
| 17932798 | COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72 | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1635 | 2 |
| 1633 | 1 |
| 1638 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693062 | ENGINEERED CASX REPRESSOR SYSTEMS | SPENCE, JENNIFER SUZANNE | 1633 | §103Other | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18608127 | SELF-INACTIVATING VECTORS FOR GENE EDITING | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18266076 | AAV VECTORS FOR GENE EDITING | CHONG, KIMBERLY | 1636 | §103§112 | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18039858 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | ZARA, JANE J | 1637 | §101§102§112 | Non-Final OA | 51d overdue | Pending | Jun 01, 2023 |
| 18255172 | COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A | SU-TOBON, QIWEN NMN | 1636 | §103§112DP | Non-Final OA | — | Pending | May 31, 2023 |
| 17932798 | COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72 | MCLEOD, AFRICA MHAIRIE | 1635 | §112 | Final Rejection | — | Pending | Sep 16, 2022 |
| 17641426 | COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 | RYAN, DOUGLAS CHARLES | 1635 | §101§103§112DP | Final Rejection | 31d overdue | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScribe Therapeutics Inc. has 7 pending office actions as of November 2026, spread across 5 art units and 7 examiners.
Jennifer Suzanne Spence has the most, with 1 of Scribe Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.